In Brief: Trinity Biotech/Centocor
This article was originally published in The Gray Sheet
Trinity Biotech/Centocor: Ink agreement under which Trinity Biotech will purchase Centocor's U.K.-based infectious disease business for $5.5 mil. Trinity Biotech acquires several microtitre enzyme immunoassay tests, including tests for toxoplasmosis, rubella, cytomegalovirus, herpes simplex virus 2, syphilis, and Chagas disease. Trinity also gains a Centocor diagnostic manufacturing facility in Guildford, England. Centocor will record a $4.5 mil. charge to earnings in connection with the transaction, which is expected to close within the next month...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.